1. Home
  2. EXEL vs CACI Comparison

EXEL vs CACI Comparison

Compare EXEL & CACI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXEL
  • CACI
  • Stock Information
  • Founded
  • EXEL 1994
  • CACI 1962
  • Country
  • EXEL United States
  • CACI United States
  • Employees
  • EXEL N/A
  • CACI N/A
  • Industry
  • EXEL Biotechnology: Biological Products (No Diagnostic Substances)
  • CACI EDP Services
  • Sector
  • EXEL Health Care
  • CACI Technology
  • Exchange
  • EXEL Nasdaq
  • CACI Nasdaq
  • Market Cap
  • EXEL 11.3B
  • CACI 9.7B
  • IPO Year
  • EXEL 2000
  • CACI 1979
  • Fundamental
  • Price
  • EXEL $44.08
  • CACI $476.81
  • Analyst Decision
  • EXEL Buy
  • CACI Strong Buy
  • Analyst Count
  • EXEL 18
  • CACI 14
  • Target Price
  • EXEL $43.00
  • CACI $508.46
  • AVG Volume (30 Days)
  • EXEL 3.3M
  • CACI 261.4K
  • Earning Date
  • EXEL 08-05-2025
  • CACI 08-06-2025
  • Dividend Yield
  • EXEL N/A
  • CACI N/A
  • EPS Growth
  • EXEL 237.58
  • CACI 22.32
  • EPS
  • EXEL 2.20
  • CACI 21.19
  • Revenue
  • EXEL $2,298,922,000.00
  • CACI $8,361,975,000.00
  • Revenue This Year
  • EXEL $9.37
  • CACI $14.60
  • Revenue Next Year
  • EXEL $11.05
  • CACI $7.33
  • P/E Ratio
  • EXEL $19.98
  • CACI $22.52
  • Revenue Growth
  • EXEL 24.49
  • CACI 14.16
  • 52 Week Low
  • EXEL $21.82
  • CACI $318.60
  • 52 Week High
  • EXEL $49.62
  • CACI $588.26
  • Technical
  • Relative Strength Index (RSI)
  • EXEL 57.96
  • CACI 64.42
  • Support Level
  • EXEL $42.66
  • CACI $454.44
  • Resistance Level
  • EXEL $49.62
  • CACI $469.13
  • Average True Range (ATR)
  • EXEL 1.58
  • CACI 12.18
  • MACD
  • EXEL 0.10
  • CACI 2.82
  • Stochastic Oscillator
  • EXEL 43.24
  • CACI 99.33

About EXEL Exelixis Inc.

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

About CACI CACI International Inc.

CACI International Inc is an information solutions and services provider, offering information solutions and services to its customers. The company's primary customers are agencies and departments of the U.S. government, which account for the vast majority of the firm's revenue. It provides information solutions and services supporting national security missions and government modernization for intelligence, defense, and federal civilian customers. Some of the services provided by the company are functional software development, data, and business analysis, IT operations support, naval architecture, and life cycle support intelligence among others. The company's operating segments are; Domestic operations and International operations. It derives key revenue from the Domestic segment.

Share on Social Networks: